New triple therapy alleviates cystic fibrosis
Two years ago, a research group headed by Charité – Universitätsmedizin Berlin showed that combination therapy involving three drugs – elexacaftor, tezacaftor, and ivacaftor – is effective in a large portion of patients with cystic fibrosis, a hereditary disease, meaning that the treatment noticeably improves both lung function and quality of life. Now, the team headed by Professor Marcus Mall, who has been the lead researcher in both studies, has investigated for the first time whether this form of treatment is also helpful in the long term, meaning over a period of 12 months or more. To examine this, the researchers took a closer look at the sputum, the secretions from patients’ respiratory tracts.
The samples were analyzed with a mass spektrometer.
“In patients with cystic fibrosis, the mucus in the airways is very sticky because it doesn’t contain enough water and the mucins, the molecules that form mucus, adhere too much due to their chemical properties. This results in thick, sticky mucus, which clogs the airways, making it harder for patients to breathe and leading to chronic bacterial infection and inflammation of the lungs,” explains Mall, Director of the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and the Christiane Herzog Cystic Fibrosis Center at Charité.
In the current study in the “European Respiratory Journal“, the researchers show that a combination of elexacaftor, tezacaftor, and ivacaftor results in less viscous respiratory secretions and decreasing inflammation and bacterial infection in the lungs of cystic fibrosis patients. “What’s more, the effects lasted over the entire one-year study period. This is really important because previous medications caused a rebound in the bacterial load in the airways,” explains Dr. Simon Gräber, who also works in the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine at Charité and was one of the co-leaders of the study. 79 adolescents and adults with cystic fibrosis and chronic lung disease participated in the trial.
No cure yet
“This is a major step forward in treating cystic fibrosis,” Mall says. “At the same time, it would be premature to say that patients have been normalized, let alone cured. Chronic lung changes arising over many years of living with the disease cannot be reversed, unfortunately.” This means patients with advanced lung disease will still need to rely on established treatments involving inhaling mucus-thinning medications, taking antibiotics, and physical therapy.
There is great potential for new proteomics methods to identify disease processes and potential biomarkers not only in conventional liquid biopsies such as blood samples but also in organ-specific sputum samples from the lungs.
“We plan to forge ahead with our research on how to make treatments that address cystic fibrosis via the molecular defects that cause the disease – like the triple medication combination studied here – even more effective. This includes starting treatment in early childhood with the goal of preventing chronic lung changes wherever possible,” Mall notes. Aside from that, this therapy is not available to about ten percent of the patients right now due to their genetic conditions.
New proteomic analyses are assisting in the search for effective treatment methods for all patients. In collaboration with Kerstin Fentker, a doctoral student at the Proteomics Platform of the Max Delbrück Center and the Berlin Institute of Health at Charité (BIH) and one of the co-first authors have further developed these analyses. They can now track molecular processes at the protein level in patient sputum over time. Dr. Philipp Mertins, co-senior author and head of the Proteomics Platform, adds, "There is great potential for new proteomics methods to identify disease processes and potential biomarkers not only in conventional liquid biopsies such as blood samples but also in organ-specific sputum samples from the lungs."
The researchers are also working to advance their understanding of mucus defects in cystic fibrosis and develop new mucolytics, drugs that thin and loosen the mucus. This research could also benefit patients with common chronic inflammatory lung diseases such as asthma and COPD.
Text: Charité
- Cystic fibrosis
-
-
Cystic fibrosis is one of the most common fatal hereditary diseases worldwide. As many as 8,000 children, teens, and adults are living with the disease in Germany today. An imbalance in salt and water transport across mucosal surfaces of the body causes people with cystic fibrosis to produce thick, sticky secretions that harm organs such as the lungs, intestine and pancreas. This leads to progressive loss of lung function and shortness of breath, which still significantly lowers life expectancy despite advances in treatment. Some 150 to 200 children are born with this rare disease in Germany each year.
- About the triple combination therapy
-
-
A combination of three drugs – elexacaftor, tezacaftor, and ivacaftor – became available in Europe in August 2020. The therapy noticeably improves lung function and quality of life in patients with the most common genetic defect involved in CF, F508del. This means the treatment is an option for nearly 90 percent of those living with cystic fibrosis. The combination therapy was approved for children starting at the age of six years in early 2022.
- About the study
-
-
The project arose in cooperation with researchers from the Max Delbrück Center and as part of the Dynamic Hydrogels at Biointerfaces (CRC 1449) collaborative research center. Prof. Mall is the deputy spokesperson for this CRC. He also holds an Einstein Professorship and is in charge of the cystic fibrosis research program at the German Center for Lung Research (DZL).
Further information
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine at Charité University Hospital Berlin
- Collaborative research center “Dynamic Hydrogels at Biointerfaces“ (SFB 1449)
Literature
Laura Schaupp, Annalisa Addante, Mirjam Völler, Kerstin Fentker et al. (2023): „Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor on Sputum Viscoelastic Properties, Airway Infection and Inflammation in Patients with Cystic Fibrosis“. European Respiratory Journal, DOI: 10.1183/13993003.02153-2022
Downloads
The samples were analyzed with a mass spektrometer. Picture: David Ausserhofer, Max Delbrück Center
Contacts
Dr. Philipp Mertins
Head of Proteomics pPlatform
Max Delbrück Center & BIH
Philipp.Mertins@mdc-berlin.de
Christina Anders
Editor, Communications
Max Delbrück Center
+49 30 9406-2118
christina.anders@mdc-berlin.de or presse@mdc-berlin.de
